Breast Adjuvant

Trial #

Title

ECOG/ ECOG  PACCT-1

Program for the Assessment of Clinical Cancer Tests (PACCT-1) Trial Assigning Individualized Options for Treatment. The TAILORx Trial

IBCSG 24-02

A Phase III trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer

NSABP/NSABP B-36

A Clinical Trial of Adjuvant Therapy Comparing Six Cycles of 5-Fluorouracil, Epirubicin, and Cyclophosphamide (FEC) to Four Cycles of Adriamycin and Cyclophosphamide (AC), with or without Celecoxib, in Patients with Node-Negative Breast Cancer.

SWOG/SWOG S0221

Phase III Trial of Continuous Schedule AC+G Vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks of Weekly for 12 weeks as Post-Operative Adjuvant Therapy in Node-Positive or High Risk Node Negative Breast Cancer

SWOG/SWOG S0307

A Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer

Breast Advanced

Trial #

Title

Amgen/Pharm 20050136

A randomized, double-blind, multicenter study of denosumab compared with zoledronic acid (Zometa) in the treatment of bone metastases in advanced breast cancer.

Genentech/Pharm AVF3693g

A phase III, multicenter, randomized, placebo-controlled trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy regimens in subjects with previously treated metastatic breast cancer

SWOG/SWOG S0226

Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First Line Therapy for Post Menopausal Women with Metastatic Breast Cancer

SWOG/SWOG S0622

Phase II studies of two different schedules of Dasatinib (NSC-732517) in bone metastasis predominant metastatic breast cancer

Breast Ancillary

Trial #

Title

INST 0703C

GPR30 in Breast Cancer: A Correlative Study

Breast Neoadjuvant

Trial #

Title

ACOSOG/ ACOSOG Z1031

A Randomized Phase III Trial Comparing 16 to 18 Weeks of Neoadjuvant Exemestane (25 mg daily), Letrozole (2.5 mg), or Anastrozole (1 mg) in Postmenopausal Women with Clinical Stage II and III Estrogen Receptor Positive Breast Cancer

ACOSOG/ ACOSOG Z1041

A Randomized Phase III Trial Compaing a Neoadjuvant Regimen of FEC-75 Followed By  Plus Trastuzumab with a Neoadjuvant Regimen of Paclitaxel Plus Trastuzumab Followed by FEC-75 Plus Trastuzumab in Patients with Palpable and Operable Breast Cancer

INST/Baylor/INST 0514C

A Neoadjuvant Phase II Trial of GW572016 in HER2 Overexpressing Breast Cancer Patients: Biologic Correlative Study

Breast Prevention

Trial #

Title

INST 0552C

Expanded Breast Cancer Registry and Tissue Repository

INST 0607C

Inherited genetic variants and breast cancer survival: A population-based study.

INST 0611C

DNA Decatenation of Breast Cancer by Metnase

NSABP/NSABP B-42

A clinical trial to determine the efficacy of five years of letrozole compared to placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor(AI) or tamoxifen followed by an AI in prolonging Disease-Free survival in postmenopausal women with hormone receptor positive breast cancer

GI Colorectal Adjuvant

Trial #

Title

NCCTG/NCCTG N0147

A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil(5-FU)/Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer

GI Colorectal Advanced

Trial #

Title

Amgen 20040249

Immunex: A Randomized, Open-label, Controlled, Clinical Trial of Chemotherapy and Bevacizumab with and without Panitumumab in the First-line Treatment of Subjects with Metastatic Colorectal Cancer

NSABP/NSABP LTS-01

Patient Reported Outcomes in Long Term Survivors with Colon and Rectal Cancer

Amgen/Pharm 0510P

Amgen 20040249 –Immunex: A Randomized, Open-label, Controlled, Clinical Trial of Chemotherapy and Bevacizumab with and without Panitumumab in the First-line Treatment of Subjects with Metastatic Colorectal Cancer

Roche/Pharm 0515P

ML1849: XELOX-A DVS (Dense Vs. Standard). A Randomized Study of Intermittent Capecitabine in Combination with Oxaliplatin (XELOX Q3W) and Bevacizumab versus Intermittent in Combination with Oxaliplatin (XELOS Q2W) and Bevacizumab as First-line Treatment for Patients with Metastatic Colorectal Cancer

Amgen/Pharm 20050181

A randomized, multicenter phase 3 study to compare the efficacy of panitumumab in combination with chemotherapy to the efficacy of chemotherapy alone in patients with previously treated metastatic colorectal cancer

Amgen/Pharm 20060141

A multi-center, open label, randomized, phase 2 clinical trial evaluating safety and efficacy of FOLFIRI with either panitumumab or bevacizumab as second-line treatment in subjects with metastatic colorectal cancer

GI Colorectal Neoadjuvant

Trial #

Title

Roche-INST 3304C

A Phase II trial using a combination of Oxaliplatin, Capecitabine, and Celecoxib with Concurrent Radiation for Patients with Newly Diagnosed Resectable Rectal Cancer

GI Colorectal Prevention

Trial #

Title

INST 0603C

INST 0603C Chart Review on Patients with Unresectable/Metastatic Pancreatic Cancer Treated in the UNM Cancer Center

GI Hepatic Adjuvant

Trial #

Title

Sanofi/Genentech/Lilly /INST OX-05-024

Phase II Trial of Gemcitabine and Oxaliplatin (Gem-Ox) with Erlotinib (Tarceva) in the Treatment of Hepatocellular Carcinoma (HCC) in patients with adequate platelets (>100,000/?L)

GI Pancreatic Adjuvant

Trial #

Title

INST 0613C

INST 0613C Retrospective analysis of responses and survival in patients with locally advanced or metastatic pancreatic cancer treated in the CRTC from 10/1/2001 to 6/30/2006

Amplimed/Pharm AMP-004

A Phase I Trial of Imexon, Injection (Amplimexon) plus Gemicitabine in Advanced, Previously Untreated Pancreatic Adenocarcinoma

GU Ancillary

Trial #

Title

HRRC 04-528

Bladder Cancer Diagnosis through NMR Spectroscopy of Urine

GU Prostate Adjuvant

Trial #

Title

RTOG 0126

A  Phase  III Randomized Study of High Dose 3D-CRT/IMRT Versus Standard Dose 3D-CRT/IMRT in Patients Treated for Localized Prostate

RTOG 0232

A Phase III Study Comparing Combined External Beam Radiation and Transperineal Institial Permanent Brachytherapy with Brachytherapy Alone for Selected Patients with Intermediate Risk Prostatic Carcinoma

SWOG 9346

Intermittent Androgen Deprivation in Patients with Stage D2 Prostate Cancer, Phase III.

CALGB 90401

A Randomized Double-Blinded Placebo Controlled Phase III Trial Comparing Docetaxel and Prednisone with and without Bevacizumab (IND#7921, NSC #704865) in Men with Hormone Refractory Prostate Cancer

CALGB 90401 VA

A Randomized Double-Blinded Placebo Controlled Phase III Trial Comparing Docetaxel And Prednisone With and Without Bevacizumab (IND #7921, NSC #704865) in Men with Hormone Refractory Prostate Cancer

HRRC 03-376

Investigation of Protein Biomarkers of Prostate Cancer

HRRC 04-458

Identification of Risk Allels for Prostate Cancer

RTOG 0126

A  Phase  III Randomized Study of High Dose 3D-CRT/IMRT Versus Standard Dose 3D-CRT/IMRT in Patients Treated for Localized Prostate Cancer

RTOG 0232

A Phase III Study Comparing Combined External Beam Radiation and Transperineal Institial Permanent Brachytherapy with Brachytherapy Alone for Selected Patients with Intermediate Risk Prostatic Carcinoma

RTOG 0415

A phase III randomized study of hypofractionated 3D-CRT/IMRT versus conventionally fractionated 3D-CRT/IMRT in patients with favorable-risk prostate cancer

RTOG 0521

A Phase III protocol of androgen suppression (AS) and 3DCRT/IMRT vs. as an 3DCRT/IMRT followed by chemotherapy with docetaxel and prednisone for localized, high risk prostate cancer

SWOG 9346

Intermittent Androgen Deprivation in Patients with Stage D2 Prostate Cancer, Phase III.

GU Prostate Advanced

Trial #

Title

CALGB 90202

A randomized double-blind, placebo-controlled phase III study of early versus standard zoledronic acid to prevent skeletal related events in men with prostate cancer metastatic to bone

RTOG 0518

A phase III, double-blind, placebo-controlled study to evaluate the efficacy of zometa® for the prevention of osteoporosis and associated fractures in patients receiving radiation therapy and long term LHRH agonists for high-grade and/or locally advanced prostate cancer

GU Prostate Neoadjuvant

Trial #

Title

E1Y03

Master Protocol for Pharmacogenetic and Genomic Studies

SWOG S0353

Phase II study of Intravesical gemcitabine in patients with superficial bladder cancer who have progressed despite intravesical BCG

GU Prostate Prevention

Trial #

Title

2904C

Prostate Cancer Diagnosis Through NMR Spectroscopy of Semen and Prostatic Secretions

GU Renal Cell Adjuvant

Trial #

Title

E2805

A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma

Pfizer/Pharm A6181065

Pfizer: A randomized phase III study of the efficacy and safety of sunitinib malate alone or in combination with interferon ALFA-2B as first-line therapy for metastatic renal cell cancer (renal EFFECT trial)

GYN Ancillary

Trial #

Title

2902C

Pre-clinical Models in Gynecological Tumors- Tissue Repository

HRRC 07-308

Assessment of genetic alterations in signaling networks as prognostic markers in cervical cancer

GYN Cervical Adjuvant

Trial #

Title

GOG 0207

A randomized Double-Blind Phase II Trial of Celecoxib, a Cox-2 Inhibitor, in the treatment of patients with Cervical intraepithelial neoplasia 2/3 or 3 (CIN 2/3 or 3)

GOG 0219

A Phase III Randomized Trial of Weekly Cisplatin and Radiation versus Cisplatin and Tirapazamine and Radiation in Stage IB2, IIA, IIB, IIIB, and IVA Cervical Carcinoma Limited to the Pelvis

GYN Cervical Advanced

Trial #

Title

GOG 0204

A Randomized Phase III Trial of Paclitaxel plus Cisplatin versus Vinorelbine plus Cisplatin versus Gemcitabine plus Cisplatin versus Topotecan plus Cisplatin in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix

GYN Endometrial Adjuvant

Trial #

Title

GOG CSF-1

CSF-1 and Other Cytokines in Human Endometrial Carcinogenesis

RTOG 0418

A phase II study of Intensity modulated radiation therapy (IMRT) to the pelvis +/- chemotherapy for post-operative patients with either endometrial or cervical carcinoma

GOG 0209

A Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF Versus Carboplatin/Paclitaxel in Patients with Stage III & IV or Recurrent Endometrial Cancer

GYN Ovarian Adjuvant

Trial #

Title

GOG 0146

A Phase II Evaluation of Irofulven (IND# 55804, NSC#683863) in the Treatment of Recurrent or Persistent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer

GOG 0198

A Randomized Study of Tamoxifen Vs Thalidomide (NSC # 66847) In Patients With Biochemical-Recurrence-Only Epithelial Ovarian Cancer, Cancer of the Fallopian Tube, and Primary Peritoneal Carcinoma After First Line Chemotherapy

HRRC 02-579

Trends in Incidence and Survivals for Ovarian Germ Cell Tumors:  A 27-Year Population-Based Study

GYN Ovarian Advanced

Trial #

Title

SCI/GlaxoSmith Kline/CRC 0503

Phase I/II Lapatinib plus carboplatin and paclitaxel in stage III or IV relapsed ovarian cancer patients or stage IV breast cancer patients

GOG 0212

A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or Xyotax (CT-2103) (IND# 70177), Versus No Treatment Until Documented Relapse in Women with Advanced Ovarian or Primary Peritoneal Cancer Who Achieve A Complete Clinical Response to Primary Platinum/Taxane Chemotherapy

GOG 0218

A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (Rhumab VEGF, NSC #704865, IND #7921) Followed by Placebo, versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women with Newly Diagnosed, Previously Untreated, Suboptimal Advanced Stage Epithelial Ovarian and Peritoneal Primary Cancer

Fresenius Biotech North America/ Pharm IP-CAT-OC-01

An open -label, single-arm, phase II safety and tolerability study of catumaxomab (anti-EpCAM x anti-CD3) in women with advanced epithelial Ovarian Cancer After a complete response to Chemotherapy

GYN Prevention

Trial #

Title

GlaxoSmithKline/04-183

A phase III, double-blind, randomized, controlled multi-center study to evaluate the efficacy of GlaxoSmithKline Biologicals HPV-16 or HPV-18 VLP/ASO4 vaccine compared to hepatitis A vaccine as control in prevention of persistent HPV-16 or HPV-18 cervical infection and cervical neoplasia, administered intramuscularly according to a 0,1, 6 month schedule in healthy females 15-25 years of age. Protocol 580299/008

1104C

Non-Invasive, real-time technology for diagnosis of cervical tissue

GOG 0136

Acquisition of Human Gynecologic Specimens and Serum to be Used in Studying the Causes, Diagnosis, Prevention and Treatment of Cancer

INST 0548C

(IRB EXEMPT) Assessment of EGFR Alterations as Prognostic Markers in Cervical Cancer

INST 0605C

Assessment of genetic alteration in the ERBB-PTEN-PI3KCA signaling network as prognostic markers in ovarian cancer

INST 0708C

Biological Study: Assessment of Genetic Alterations in the Signaling Network as Prognostic Markers in Ovarian Cancer

GYN Uterine Adjuvant

Trial #

Title

GOG 0211

A Phase II Pilot Investigation of the Relationship of Short Term Depo-Provera (Medroxyprogesterone Acetate) (NSC #27408) Exposure to the Morphologic, Biochemical, and Molecular Changes in Primary Endometrioid Adenocarcinoma of the Uterine Corpus

Head and Neck Adjuvant

Trial #

Title

INST 0612C

Relationship of Mucositis Severity to Nutrition Intake in Head and Neck Cancer Patients

Head and Neck Advanced

Trial #

Title

SWOG S0618

Phase II Evaluation of E7389 (NSC-707389) in Patients with Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck

Hematology Acute Leukemia

Trial #

Title

ECOG E1905

A Randomized Phase II Trial of Azacitidine with or without the Histone Deacetylase Inhibitor MS-275 for the Treatment of Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia(dysplastic type), and Acute Myeloid Leukemia with Multilineage, Dysplasia

INST 0551C

Project 4 Dynamic Analysis of Signaling Networks in Leukemia

Novartis/Pharm CAMN107A2109

An open-label, multi-center, expanded access study of oral AMN107 in adult patients with imatinib (Glivec®/Gleevec®)- resistant or- intolerant chronic myeloid leukemia in blast crisis, accelerated phase or chronic phase

SWOG S0106

A Phase III Study of the Addition of Gemtuzumab Ozogamicin (Mylotarg®) Induction Therapy Versus Standard Induction With Daunomycin and Cytosine Arabinoside Followed by Consolidation and Subsequent Randomization to Post-Consolidation Therapy With Gemtuzumab Ozogamicin (Mylotarg®) or No Additional Therapy for Patients Under Age 61 With Previously Untreated De Novo Acute Myeloid Leukemia (AML)

SWOG S0333

A Phase II Study of Double Induction Chemotherapy for Newly Diagnosed Non-L3 Adult Acute Lymphoblastic Leukemia with Investigation of Minimal Residual Disease and Risk of Relapse Following Maintenance Chemotherapy

Hematology Ancillary

Trial #

Title

SWOG 9007

Cytogenetic Studies in Leukemia Patients, Ancillary.  Includes SWOG 9300 and 9126.  Please check protocol for additional information.

SWOG S9910

Leukemia Centralized Reference Laboratories and Tissue Repositories, Ancillary.

Hematology Chronic Leukemia

Trial #

Title

INST 0618C

INST 0618C:  Disparaties in chronic lymphocytic leukemia survival and relationship with DNA repair gene polymorphisms in New Mexico

Hematology Lymphoma Hodgkins

Trial #

Title

Amgen/Pharm 0540P – Amgen 20050144

An Open Label Dose (and/or Schedule) Finding Trial to Evaluate the Safety and Efficacy of AMG 531 for Treatment of Severe Thrombocytopenia Due to Multi-Cycle Chemotherapy in Adult Subjects with Relapsed Aggressive Lymphoma

Hematology Lymphoma Non-Hodgkins

Trial #

Title

CALGB 50303

Phase III Randomized Study of R-CHOP V. Dose-Adjusted EPOCH with molecular profiling in untreated De Novo Diffuse Large B-Cell Lymphomas

INST 1003C

Phase II study: Treatment of relapsed lymphoid malignancies with an anti-angiogenic approach

Hematology Myeloma

Trial #

Title

AnorMed/Pharm AMD3100-CUP001

AnorMed, Inc. AMD3100-CUP001: Compassionate use protocol for the Use of AMD3100 to Mobilize Peripheral Blood Stem Cells for Collection and Transplantation

SWOG S0309

Myeloma Specimen Repository Protocol, Ancillary

SWOG S0434

A phase II trial of BAY 43-9006 (Sorafenib) (NSC-724772) in patients with relapsing or resistant multiple myeloma previously treated with bortezomib

Lung Ancillary

Trial #

Title

2903C

Lung Cancer Case Registry

SWOG S9925

Lung Cancer Specimen Repository Protocol, Ancillary.

Lung Mesothelioma Adjuvant

Trial #

Title

 3704P

Multicenter Randomized Comparative Phase III Trial of Onconase® + Doxorubicin vs Doxorubicin in Patients with Malignant Mesothelioma

SWOG S0509

A Phase II Study of Novel Oral Anti-Angiogenic Agent AZD2171 (NSC-732208) in Malignant Pleural Mesothelioma

Lung NSCLC Advanced

Trial #

Title

SWOG E5597

Phase III Chemoprevention Trial of Selenium Supplementation in Persons with Resected Stage Non-Small Cell Lung Cancer

INST 0529C

Phase I study of concurrent radiotherapy with weekly Topotecan for primary treatment of inoperable localized non-small cell lung cancer (NSCLC) (Stage I to IIIA).

Genentech/INST 0601C

A Randomized Phase II Protocol of Erlotinib versus Standard Platinum-Based Chemotherapy in Patients with Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung

INST 0701C

An observational outcomes protocol of Standard Practice of Best Supportive Care with or without surgery, Chemotherapy or Radiotherapy in Patients with Carcinoma of the Lung

INST 0704C

Aberrant Histone Function in Lung Cancer

ImClone/harm 0505P

CP02-0452: Randomized Phase III Study of Docetaxel or Pemetrexed with or without Cetuximab in Patients with Recurrent or Progressive Non-Small Cell Lung Cancer (NSCLC)after Platinum-Based Therapy

Pharm 20030185

A Phase 2 Study to Evaluate the Efficacy and Safety of Palifermin (Recombinant Human Keratinocyte Growth Factor) in the Reducation of Dysphagia in Patients Receiving Concurrent Chemoradiotherapy followed by Consolidation Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

PPD/Genentech Pharm AVF3991n

An observational study of Avastin (bevacizumab) in combination with chemotherapy for treatment of metastatic or locally advanced and unresectable colorectal cancer, locally advanced or metastatic non-small cell lung (excluding predominant squamous cell histology), or locally recurrent or metastatic breast cancer

Novartis Pharm CRAD001C2111

A combined phase 1 and 2 study investigating the combination of RAD001 and erlotinib in patients with advanced NSCLC previously treated only with chemotherapy

OSI Pharm OSI-774-302

A multi-center, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA Non-small Cell Lung Carcinoma who have EGFR-positive Tumors

Pharmacyclics Pharm PCYC-0228

Phase II trial of Motexafin Gadolinium and Pemetrexed (Alimta) for Second Line Treatment in Patients with Non-Small Cell Lung Cancer

Lung NSCLC Neoadjuvant

Trial #

Title

INST 0701C

An observational outcomes protocol of Standard Practice of Best Supportive Care with or without surgery, Chemotherapy or Radiotherapy in Patients with Carcinoma of the Lung

Lung SCLC Advanced

Trial #

Title

Eli Lilly PHARM H3E-MC-JMHO

A Randomized Phase 3 Trial of ALIMTA (Pemetrexed) and Carboplatin versus Etoposide and Carboplatin in Extensive-Stage Small Cell Lung Cancer (GALES Study)

Skin Melanoma Adjuvant

Trial #

Title

Bristol Meyers Squibb/CA184025

A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010) Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols

i3 research/Pharm CA184024

A Multi-Center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients with Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg of Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

SWOG S0008

Phase III Trial of High Dose Interferon Alpha-2b Versus Cisplatin, Vinblastine, DTIC Plus IL-2 and Interferon in Patients with High Risk Melanoma.

SWOG S0008

Phase III Trial of High Dose Interferon Alpha-2b Versus Cisplatin, Vinblastine, DTIC Plus IL-2 and Interferon in Patients with High Risk Melanoma.

Skin Melanoma Advanced

Trial #

Title

SWOG E4697

A Randomized, Placebo-Controlled Phase III Trial of Yeast Derived GM-CSF Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients with No Evidence of Disease after Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma

Administrative

Trial #

Title

CA-9909

Grant Application: #CA-9909 Minority Based Community Clinical Oncology Program

INST 0707C

Research Supplements to Promote Diversity in Health Related Research

No Study Available

This is to keep track of patients who were screened but no study was available for them.

INST S9808

Long Term Follow-up Protocol: An Administrative Tool

Advanced Solid Tumors

Trial #

Title

 0100C

Phase I Dose Finding Clinical Trial of Combination Paclitaxel, Carboplatin and Temozolomide for Subjects with Solid Tumor Malignancies.

Pfizer 3604P

A Phase 1 Safety and Pharmacokinetic Study of SU011248 and Capecitabine in Patients with Advanced Solid Tumors

Pharm 0518P

A Treatment Protocol for Patients Continuing from a Prior SU011248 Protocol (Protocol A6181030)

Pharm 0530P

An open label, phase I study to evaluate the safety, tolerability, and pharmacokinetics of patupilone in patients with advanced solid tumors and varying degrees of hepatic function

Novartis/ Pharm CEPO906A2105

A phase Ib, multicenter, open-label, dose-finding study of patupilone administered intravenously every 3 weeks in combination with carboplatin AUC 6 in adult patients with advanced solid tumors

Eli Lilly/Pharm I1Y-MC-JFBA

A phase 1 study of LY2523355 in patients with advanced cancer

Pharm SPO-0011

Phase 1 Open Label, Multicenter, Dose Escalating, Clinical Study of Safety, Tolerability and Pharmacokinetic and Pharmacodynamic Profiles of SNS -314, a novel aurora kinase inhibitor, administered to patients with advanced solid tumors

PHARM Vioquest 7059

A Phase I/IIa, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sodium Stibogluconate in Combination with Interferon Alpha-2b for Patients with Advanced Malignancies

TPU S1111

A Phase 1, Open-Label Study Evaluating the Pharmacokinetics of Components of S-1 in Patients with varying Degrees of Renal Function

Ill Defined

Trial #

Title

INST 0538C

A Pilot Study of the Correlation between Tumor c-Met Expression and Thrombosis in Cancer Patients

INST 0709C

(IRB EXEMPT) Collection of Controls – Correlative Study for Institutional Translational Protocols

Sarcoma Adjuvant

Trial #

Title

INST/Eli Lilly & Co/INST 0509C

Phase I/II Study of Gemcitabine, Docetaxel and Bevacizumab in Patients with Soft Tissue Sarcoma

Sarcoma Advanced

Trial #

Title

Eli Lilly/Pharm H8K-MC-JZAD

A phase 2 Study of LY573636- sodium administered as second-line or third-line treatment in Patients with Unresectable or Metastatic Soft Tissue Sarcoma

Sarcoma Neoadjuvant

Trial #

Title

INST 0517C

Chart review of treatments received by patients diagnosed with soft tissue sarcoma

Supportive Care Protocols

Trial #

Title

4004C

PCRT Pancreatic Cancer Serum and DNA Repository

GOG/GOG 0215

A phase II randomized study of the effect of zoledronic acid versus observation on bone mineral density of the lumbar spine in women who elect to undergo risk-reducing surgery that results in the removal of both ovaries

INST 0527C

The Meaning of Cancer Survivorship for Hispanic Adolescents: A Qualitative Pilot Study

INST 0535C

Investigator Initiated Trial: Prospective Study of Clinical Predictors of Survival in Cancer Patients with Metastatic Solid Tumors

INST 0547C

Expressive Writing Group for Cancer Survivors

INST 0549C

Differences in 30-year Trends in Incidence and Survival for Malignant Germ Cell Tumors in Males and Females: A SEER Population-based Study

INST 0553C

A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients

INST 0604C

Bevacizumab (Avastin) induced hypertension and correlation with tumor response, a chart review.

Pediatric Trials

Trial Number

Protocol Name

COG  Registry

COG Diagnosis Registry

COG 9346

Hepatoblastoma Biology Study and Tissue Bank

COG 9442

National Wilms Tumor Late Effect Study

COG AALL0232

High Risk B-precursor Acute Lymphoblastic Leukemia

COG AALL02P2

Treatment of Late Isolated Extramedullary Relapse from Acute Lymphoblastic Leukemia (ALL) (Initial CR1>/=18 months)

COG AALL0331

Standard Risk B-precursor Acute Lymphoblastic Leukemia

COG AALL03B1

Classification of Acute Lymphoblastic Leukemia

COG AALL03N1

Understanding the Role of Adherence in the Ethnic Differences in Survival after Childhood ALL

COG AALL0433

Phase 3 Study -Intensive treatment for intermediate risk relapse of childhood B-Precursor Acute Lymphomblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies

COG AALL0434

Intensified Methotrexate, Nelarabine (Compound 506U78; IND#52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia

COG AALL05B1

A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens

COG AALL06N1

A study of neurocognitive function in children treated for ALL: (A groupwide, non-therapeutic companion study to AALL0232 and AALL0434)

COG AAML0431

The treatment of down syndrome children with acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Under the age of 4 years: Phase III Study

COG AAML0531

A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg®) Combined with Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults

COG ACCL05C1

A group wide, prospective study of ototoxicity assessment in children receiving cisplatin chemotherapy
(A group wide non therapeutic study)

COG ACNS0122

A Phase II Study to Assess the Ability of Neoadjuvant Chemotherapy +/- Second Look Surgery To Eliminate All Measurable Disease Prior to Radiotherapy For NGGCT

COG ACNS0221

A Phase II Study of Conformal Radiotherapy in Patients with Low-Grade Glioma

COG ACNS0232

A Phase III groupwise study -Radiotherapy Alone vs. Chemotherapy Followed by Response-Based Radiotherapy for Newly Diagnosed Primary CNS Germinoma

COG ACNS0331

A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy 18.00 Gy and Chemotherapy In Children with Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial

COG ACNS0332

A groupwide phase III study- Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than average risk medulloblastoma/PNET patients

COG ADVL04P2

A feasability pilot and phase 2 study of chemoimmunotherapy with Epratuzumab for children with relapsed CD22-Positive Acute Lymphoblastic Leukemia

COG ADVL0524

Phase II Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Children and Young Adults with Refractory Solid Tumors

COG AEPI04C1

Low Birth Weight & Other Risk Factors for Hepatoblastoma- A Groupwide Protocol

COG AEWS02B1

A Groupwide Biology and Banking Study for Ewing Sarcoma

COG AEWS0331

European Ewing Tumour Working Initiative of National Groups Ewing Tumour Studies 1999 (EURO-E.W.I.N.G.99)

COG AEWS0621

Phase II trial of Intermediate -Dose Cytarabine to Modulate EWS/FLI for children and young adults with recurrent or refractory ewing sarcoma

COG AGCT0132

A Phase III Study of Reduced Therapy in the Treatment of Children With Low and Intermediate Risk Extracranial Germ Cell Tumors

COG AHOD0031

A Phase III Study of Dose-Intensive, Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents with Newly Diagnosed Intermediate Risk Hodgkin Disease

COG AHOD03P1

Treatment of Children with Newly-Diagnosed Low Stage Lymphocyte Predominant Hodgkin Disease (LPHD)

COG AHOD0431

Phase III Study for the Treatment of Children and Adolescents with Newly Diagnosed Low-Risk Hodgkin Disease

COG AHOD04B1

Hodgkin Disease (HD) Banking Study

COG ALTE03N1

Key Adverse Events after Childhood Cancer

COG ANBL0032

Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue

COG ANBL00B1

Neuroblastoma Biology Study.

COG ANBL00P2

Perinatal Neuroblastoma: Expectant Observation. A Children’s Oncology Group Pilot Study

COG ANBL0322

A Phase II study of hu14.18-IL2* (BB-IND-9728) in Children with Recurrent or Refractory Neuroblastoma

COG ANBL0421

A Phase II Study of Irinotecan + Temozolomide in Children with Recurrent Neuroblastoma

COG ANHL0131

A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) with Standard APO (Doxorubicin, Prednisone, Vincristine) versus Consolidation with a Regimen Including Vinblastine

COG AOST0221

A Phase II Study of Aersolized GM-CSF (NSC#613795, IND#11042) in Patients with First Pulmonary Recurrence of Osteosarcoma

COG AOST0331

A Randomized Trial of the European and American Osteosarcoma Study Group to Optimize Treatment Strategies for Resectable Osteosarcoma Based on Histological Response to Pre-Operative Chemotherapy

COG ARAR0331

Treatment of Childhood Nasopharyngeal Carcinoma with Neoadjuvant Chemotherapy and Concomitant Chemoradiotherapy

COG AREN0321

Treatment of High Risk Renal Tumors

COG AREN03B2

Renal Tumors Classification, Biology, and Banking Study

COG AREN0532

Treatment for Very Low, Low and Standard Risk Favorable Histology Wilms Tumor

COG AREN0533

Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors: A Groupwide Phase III study

COG ARET0332

A Study of Unilateral Retinoblastoma With and Without Histopathologic High-Risk Features and the Role of Adjuvant Chemotherapy

COG ARST0331

Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients with Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma

COG ARST0332

A groupwise phase III Study-Risk Based Treatment for Pediatric Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS)

COG ARST0431

Intensive Multi-Agent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide (IE) and Vincristine/Doxorubicin/Cyclophosphamide (VDC) for Patients with High-Risk Rhabdomyosarcoma

COG ARST0531

(Groupwide Phase III)Randomized study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) versus VAC Alternating with Vincristine and Irinotecan (VI) for Patients with Intermediate-Risk Rhabdomyosarcoma(RMS)

COG D9902

A COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol

COG E1697

Phase III Randomized Study of Four Weeks High Dose IFN 2b in Stage T3-T4 or N1 (microscopic) Melanoma

COG LTF

A Groupwide Procedure for Collecting Long Term Follow Up Data

COG P9851

Osteosarcoma Biology Protocol: Companion to Group-Wide Therapeutic Studies

COG Spirituality

Spirituality in Children with Cancer (A COG Study)

H-6927

Gene Expression in Langerhans Cell Histiocytosis (LCH)

H-9926-LCH III

Treatment Protocol of the Third International Study for Langerhans Cell Histiocytosis